ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Other Income / Expenses

Net non-operating gains and losses, such as investment results, currency effects, and one-off items.

ImageneBio IncNASDAQ: IMA

Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026

Other income / expenses dips below year-ago levels

Q1 FY2026 other income / expenses of $1.47M fell 33.3% year over year, behind the +5.4% change in trailing-twelve-month other income / expenses. Sequentially, it rose 11.4% from the prior quarter. Over 3 fiscal years it compounded at +8.8% a year.

Context

  • Other income / expenses amounted to 344.0% of revenue in FY2025, up 331.3 pp from a year earlier.
  • Other income / expenses increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -33.3% toward the trailing-twelve-month pace of +5.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.47M+11.4% QoQ
Last fiscal yearDec 2025
$2.75M+518.4% YoY
LTMMar 2026
$10.53M+5.4% YoY
Other Income / Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-33.3%——
1 year+518.4%——
3-year CAGR+8.8%——
5-year CAGR——
10-year CAGR——

Other Income / Expenses history

USD · from the income statement

Latest · FY2025
2.75M USD
Year-over-year change
+518.4%
4-year CAGR
+230.7%

Other Income / Expenses vs competitors

How IMA compares with its peers on the latest reported figures

  • Peers report in different currencies, so other income / expenses is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +5.4% is the 2nd highest of 9, against a peer median of -42.9%.
  • Over three fiscal years its annual growth of +8.8% compares with a peer median of +45.1%.
IMA Competitors
Other Income / Expenses for IMA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OVIDOvid Therapeutics Inc.LTM Mar 2026$23.57M USD-26.4%+162.8%330.9%
IMAImageneBio IncLTM Mar 2026$10.53M USD+5.4%+8.8%—
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$5M USD-50.6%+65.3%—
KLRSKalaris Therapeutics IncLTM Mar 2026$3.53M USD+1344.0%——
CNTXContext Therapeutics Inc.LTM Mar 2026$3.29M USD-17.6%+87.2%—
CNTBConnect Biopharma Holdings LimitedFY2025$2.79M USD-60.4%+22.4%4360.9%
STTKShattuck Labs, Inc.LTM Mar 2026$2.79M USD-35.2%+24.9%279.0%
IFRXInflaRx N.V.LTM Mar 2026-€440.14K EUR-104.4%-1.4%1500.6%
STROSutro Biopharma, Inc.LTM Mar 2026-$38.64M USD-613.7%—38.8%
Peer median (excluding IMA) —-42.9%+45.1%330.9%

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.